PlaquEx contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming.


Secondary prevention of atherothrombotic events
Clopidogrel is indicated in:
– adult patients suffering from myocardial infarction (from a few days to 35 days), ischaemic stroke (from the 7th day to the 6th month) or established peripheral arterial disease;
– adult patients suffering from acute coronary syndrome:
– non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
– ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

Subject to medical prescription.

Concentration and pharmaceutical form: 75 mg film-coated tablets